<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576744</url>
  </required_header>
  <id_info>
    <org_study_id>FHE4-2010</org_study_id>
    <nct_id>NCT01576744</nct_id>
  </id_info>
  <brief_title>Serum Biomarker HE4 During IVF Treatment</brief_title>
  <acronym>FHE4</acronym>
  <official_title>Serum Concentration of HE4, a New Marker for Ovarian Cancer, Changes Little Throughout IVF Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Human epididymal secretory protein 4 (HE4) is a new biomarker for ovarian cancer. The effect
      of IVF stimulation will be evaluated in order to see whether severe hormonal changes in the
      gonadotrophin and steroid status affect the serum levels of this marker. Findings will be
      compared to serum concentrations of CA-125, which is currently the most often used marker for
      ovarian cancer.

      The intention is to determine the serum concentration of HE4 and CA-125 in serial samples in
      20 women undergoing IVF stimulation. Samples will be taken following GnRH agonist
      suppression, 2-3 times during FSH stimulation, at ovum pick up and two weeks following embryo
      transfer at the time of the hCG-test. The ovarian follicle count and the serum estradiol
      concentrations are recorded throughout the treatment. The serum biomarker HE4 is expected to
      ba a stable marker, which does not respond significantly to hormonal stimulation.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <primary_completion_date type="Anticipated">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">20</enrollment>
  <condition>IVF Treatment</condition>
  <condition>Human Epididymal Secretory Protein E4</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Repeated serum samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Finnish caucasian women being treated for infertility by in vitro-fertilization
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  infertility treated by IVF

        Exclusion Criteria:

          -  pelvic tumor

          -  overweight (BMI over 35)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>27 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antti H Perheentupa, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics and Gynecology, Turku University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2012</study_first_submitted>
  <study_first_submitted_qc>April 10, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2012</study_first_posted>
  <last_update_submitted>June 1, 2012</last_update_submitted>
  <last_update_submitted_qc>June 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Turku University Hospital</investigator_affiliation>
    <investigator_full_name>Antti Perheentupa</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>HE4</keyword>
  <keyword>IVF</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Infertility</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

